# Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)

Study · id `cardio:ct-nct07468448` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07468448](<https://clinicaltrials.gov/study/NCT07468448>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07468448

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1172 participants.

## Technical summary

Registry record NCT07468448. Randomized; quadruple masking; primary purpose prevention. Start 2026-09-30 (anticipated); primary completion 2029-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1172 participants (planned count; ClinicalTrials.gov record NCT07468448, source copy `cardio:ctgov-nct07468448-2026-09-01`, retrieved 2026-10-26)
- Planned start: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT07468448, source copy `cardio:ctgov-nct07468448-2026-09-01`, retrieved 2026-10-26)
- Primary completion: 2029-12-30 (anticipated) (ClinicalTrials.gov record NCT07468448, source copy `cardio:ctgov-nct07468448-2026-09-01`, retrieved 2026-10-26)
- Completion: 2029-12-30 (anticipated) (ClinicalTrials.gov record NCT07468448, source copy `cardio:ctgov-nct07468448-2026-09-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07468448-2026-09-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
- Acronym: CATIS-ICAS
- Condition: Ischemic Stroke
- Condition: Intracranial Atherosclerosis
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): ASA
- Lead sponsor: Population Health Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Population Health Research Institute (`cardio:org-population-health-research-institute`)

## Provenance

Content hash: 0bf11bcac81d93177740e4c53e6b1cbfb44feab5004a8d9241a19a72b10e4d9b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
